CTC Alternative Strategies Ltd. grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 3,139.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 121,150 shares of the company’s stock after acquiring an additional 117,410 shares during the quarter. Johnson & Johnson accounts for 27.2% of CTC Alternative Strategies Ltd.’s portfolio, making the stock its biggest holding. CTC Alternative Strategies Ltd.’s holdings in Johnson & Johnson were worth $22,464,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently modified their holdings of JNJ. Norges Bank purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth about $4,877,174,000. Laurel Wealth Advisors LLC grew its position in Johnson & Johnson by 15,040.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock valued at $1,133,512,000 after purchasing an additional 7,371,687 shares during the last quarter. Capital International Investors increased its stake in Johnson & Johnson by 545.6% during the 3rd quarter. Capital International Investors now owns 3,865,050 shares of the company’s stock valued at $716,657,000 after purchasing an additional 3,266,354 shares in the last quarter. Amundi raised its holdings in Johnson & Johnson by 19.3% in the third quarter. Amundi now owns 13,354,936 shares of the company’s stock worth $2,512,719,000 after buying an additional 2,163,838 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in Johnson & Johnson by 126.3% in the third quarter. Marshall Wace LLP now owns 3,584,162 shares of the company’s stock worth $664,575,000 after buying an additional 2,000,609 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 30,142 shares of company stock worth $7,360,528. Insiders own 0.16% of the company’s stock.
Johnson & Johnson Trading Up 0.2%
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on JNJ shares. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Wolfe Research increased their target price on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. Freedom Capital lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Citigroup boosted their price target on Johnson & Johnson from $250.00 to $274.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Finally, Daiwa Securities Group upped their price target on Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $236.91.
View Our Latest Stock Analysis on JNJ
Key Headlines Impacting Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: FDA approval of Icotyde opens a new, convenient oral IL‑23R treatment for moderate‑to‑severe plaque psoriasis — a potential multi‑billion‑dollar growth driver that directly expands J&J’s immunology portfolio and pressures injectable rivals. FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
- Positive Sentiment: HSBC raised its J&J price target to $280 and reiterated a Buy, citing healthcare strength — a clear bullish signal that can support further upside. HSBC Raises Johnson & Johnson (NYSE:JNJ) Price Target to $280.00
- Positive Sentiment: Morgan Stanley and other analysts continue to back J&J’s growth outlook around Icotyde (Morgan Stanley kept a Buy and $262 PT), reinforcing bullish institutional sentiment. Early Icotyde Approval Strengthens Johnson & Johnson’s Immunology Growth Outlook and Multi‑Billion‑Dollar Potential
- Positive Sentiment: Positive analyst/commentary pieces (e.g., The Motley Fool) argue J&J’s diversified franchises and new drugs justify a buy-and-hold stance, supporting longer‑term investor interest. 2 Reasons to Buy Johnson & Johnson Stock Like There’s No Tomorrow
- Neutral Sentiment: Barclays raised its target to $234 but kept an Equal‑Weight rating, implying limited near‑term upside from that shop and signaling mixed views across brokers. Benzinga
- Neutral Sentiment: Online investor interest and searches for JNJ have spiked (Zacks notes heavy attention), which can increase volatility but doesn’t guarantee direction. Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
- Neutral Sentiment: General dividend-planning content (e.g., pieces on how much to invest to get $100k in dividends) may drive some investor interest in JNJ’s yield, but it’s not a company‑specific catalyst. How Much Do you Need To Invest to Make $100k On Dividends Right Now?
- Negative Sentiment: Market/macro skepticism is limiting upside: commentators like Jim Cramer note J&J “should have gone higher” but broader stagflation concerns and a tough tape are keeping buyers cautious, which can cap short‑term gains. Jim Cramer on Johnson & Johnson: “It Should Have Gone Higher, But It Just Shows You How Hard It Is to Buck Stagflation Theories”
- Negative Sentiment: Recent short-term weakness (coverage noting a recent slide) highlights vulnerability to market rotation and headline-driven volatility despite fundamental wins. Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
Johnson & Johnson Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Further Reading
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
